Compare NetEase Inc (NTES) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetEase Inc vs TG Therapeutics Inc — how do they compare? NetEase Inc trades at $124.24 (market cap $76.09B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: NetEase Inc is far larger — about 9.3× TG Therapeutics Inc's market cap, and NetEase Inc pays a 2.45% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold NetEase Inc for 73 Days and TG Therapeutics Inc for 16 Days on average.
| NTES | TGTX | |
|---|---|---|
Market Cap | $76.09B | $8.16B |
Volume | 486,447 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $152.85 | $59.06 |
52-Week Low | $109.26 | $26.94 |
Typical Hold Time | 73 Days | 16 Days |
Enterprise Value | $51.81B | $8.37B |
Dividend Yield | 2.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTES trades at $124.24, up 3.01% today, with a neutral technical signal and bearish moving averages. The stock shows strong fundamentals with a P/E of 15.92, net income margin of 27.88%, and robust cash flow from operations of $50.74 billion in 2025. Recent earnings were mixed, with a Q2 2026 miss but a Q1 2026 beat. Analyst consensus is strongly bullish with an $168 price target. News highlights focus on earnings results and long-term dividend growth potential.
The outlook for NTES is positive, supported by strong profitability, a healthy balance sheet, and analyst optimism. Key opportunities include revenue growth and AI investments, while risks involve earnings volatility and competitive pressures in the gaming sector. The stock presents a compelling case for growth investors seeking exposure to China's tech sector.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
